Next-generation Diagnostics Outlook, 2022

Next-generation Diagnostics Outlook, 2022

Recovery in Routine Testing and Focus on Personalized Diagnostics to Propel Growth

RELEASE DATE
14-Mar-2022
REGION
North America
Research Code: K73A-01-00-00-00
SKU: HC03519-NA-MO_26372
$4,950.00
In stock
SKU
HC03519-NA-MO_26372
$4,950.00
DownloadLink

Pay by invoice

ENQUIRE NOW

Description

In vitro diagnostics introduces new technologies, sequencing methods, novel software algorithms, and multi-omics approaches to realise the goal of personalized medicine. Next-generation diagnostics has been the backbone of COVID-19-related emergency diagnosis, with an estimated 25% to 30% of revenue during 2020 and early 2021 related to this testing.

With the arrival of blood-based assays for chronic disease screening and next-generation molecular and point-of-care diagnostics for COVID-19-related testing, the global market grew 15.5% in 2021. Digital health solutions (patient portal + mobile app) facilitate a dramatic shift in care delivery from traditional to alternative sites, simplifying accessibility of diagnostic tests, and delivering an automated testing experience for labs to ensure rapid scalability. Patients have greater access control/faster turnaround time to results; providers can triage patients quickly through an efficient and connected workflow.

An accelerated approval pathway would foster rapid development over the next few years. The increase in availability of home care kits, spike in demand for assays and consumables, compactness of devices, and automation of workflows to serve a broad spectrum of settings are growth vectors. Early detection to initiate optimal treatment plans is a paradigm shift in personalized care.

The outlook report forecasts revenue for molecular diagnostics, point-of-care testing, clinical chemistry and immunoassays. It considers strategic imperatives, macroeconomic trends, and growth opportunities, and presents 5 predictions for 2022.

Author: Amartya Bose

RESEARCH: INFOGRAPHIC

This infographic presents a brief overview of the research, and highlights the key topics discussed in it.
Click image to view it in full size

Table of Contents

Why Is It Increasingly Difficult to Grow?

The Strategic Imperative 8™

The Impact of the Top Three Strategic Imperatives on Next-generation Diagnostics

Growth Opportunities Fuel the Growth Pipeline Engine™

Analysis Highlights

2021 Revenue Breakdown

Top Predictions for 2022

Market Segmentation

Growth Environment

Global GDP Growth

2022 Global GDP Growth Snapshot

Supply Chain Disruptions Impact Analysis

Accessibility Initiatives Impact Analysis

Revenue Forecast by Segment

Revenue Forecast by Segment (continued)

Prediction 1

Prediction 2

Prediction 3

Prediction 4

Prediction 5

Clinical Chemistry and Immunoassays Market Snapshot

Molecular Diagnostics Market Snapshot

POCT Market Snapshot

In Vitro Diagnostics Companies to Watch

Growth Opportunity 1—Liquid Biopsy as a Biomarker-driven Tool for Precision Oncology

Growth Opportunity 1—Liquid Biopsy as a Biomarker-driven Tool for Precision Oncology (continued)

Growth Opportunity 2—Decentralized and Point-of-Care Molecular Testing for Infectious Disease

Growth Opportunity 2—Decentralized and Point-of-Care Molecular Testing for Infectious Disease (continued)

Growth Opportunity 3—Smart Labs as a Service for the Digital Transformation of Diagnostic Laboratories

Growth Opportunity 3—Smart Labs as a Service for the Digital Transformation of Diagnostic Laboratories (continued)

Conclusions and Future Outlook

Your Next Steps

Why Frost, Why Now?

List of Exhibits

Legal Disclaimer

Related Research
In vitro diagnostics introduces new technologies, sequencing methods, novel software algorithms, and multi-omics approaches to realise the goal of personalized medicine. Next-generation diagnostics has been the backbone of COVID-19-related emergency diagnosis, with an estimated 25% to 30% of revenue during 2020 and early 2021 related to this testing. With the arrival of blood-based assays for chronic disease screening and next-generation molecular and point-of-care diagnostics for COVID-19-related testing, the global market grew 15.5% in 2021. Digital health solutions (patient portal + mobile app) facilitate a dramatic shift in care delivery from traditional to alternative sites, simplifying accessibility of diagnostic tests, and delivering an automated testing experience for labs to ensure rapid scalability. Patients have greater access control/faster turnaround time to results; providers can triage patients quickly through an efficient and connected workflow. An accelerated approval pathway would foster rapid development over the next few years. The increase in availability of home care kits, spike in demand for assays and consumables, compactness of devices, and automation of workflows to serve a broad spectrum of settings are growth vectors. Early detection to initiate optimal treatment plans is a paradigm shift in personalized care. The outlook report forecasts revenue for molecular diagnostics, point-of-care testing, clinical chemistry and immunoassays. It considers strategic imperatives, macroeconomic trends, and growth opportunities, and presents 5 predictions for 2022. Author: Amartya Bose
More Information
Author Amartya Bose
GPS Codes 9600-B1,9825-B1,9A06-B1,9562-B1,9573-B1,99C6-B1,99C9-B1,9627-B1
Industries Healthcare
No Index No
Is Prebook No
Podcast No
WIP Number K73A-01-00-00-00